BRANFORD, Conn. / Aug 13, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 237,068 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si (or following a bona fide period of non-employment), as an inducement material to such individuals entering into employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The RSUs will vest 25% on September 20, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued employment with Quantum-Si on such vesting dates. The RSUs are subject to the terms and conditions of the 2023 Inducement Plan and a RSU agreement covering the grant.
About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.
Last Trade: | US$2.27 |
Daily Change: | -0.27 -10.63 |
Daily Volume: | 21,579,841 |
Market Cap: | US$414.410M |
September 23, 2025 September 08, 2025 August 05, 2025 June 17, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load